Fig. 6

Brain M42 matrisome coverage and SMOC1 levels in CSF and plasma. A–G Coverage of the M42 matrisome module by proteomic platform in CSF and plasma (A). B Differences in SMOC1 relative abundance as measured by Olink between control and AD cases in CSF (left) and plasma (right). C Differences in SMOC1 relative abundance as measured by Olink between control and PD cases in CSF (left) and plasma (right) in the Accelerating Medicines Partnership – Parkinson’s Disease (AMP-PD) cohort. D Differences in SMOC1 relative abundance as measured by TMT-MS among control (n=18), AD (n=17), amyotrophic lateral sclerosis (ALS, n=19), PD (n=13), and frontotemporal dementia (FTD, n=11) subjects, a cohort previously described in Higginbotham et al. [7]. E Correlation of relative SMOC1 levels between CSF and plasma. F Correlation of SMOC1 relative abundance with CSF Aβ/T-Tau ratio in CSF (left) and plasma (right). G Correlation of SMOC1 relative abundance with age in CSF (left) and plasma (right) in the AMP-PD cohort. Differences between groups were assessed by t test or one-way ANOVA with Tukey test. Correlations were performed using Pearson correlation. Aβ, amyloid-β; TMT-MS, tandem mass tag mass spectrometry; SMOC1, SPARC-related modular calcium-binding protein 1; T-Tau, total tau. *<0.05, **<0.01, ***<0.001